Andere Kunden interessierten sich auch für
![La neutropénie et sa prise en charge chez les patients cancéreux sous chimiothérapie]( "La neutropénie et sa prise en charge chez les patients cancéreux sous chimiothérapie")
La neutropénie et sa prise en charge chez les patients cancéreux sous chimiothérapie32,99 €![Neutropenie und ihr Management bei Krebspatienten unter Chemotherapie]( "Neutropenie und ihr Management bei Krebspatienten unter Chemotherapie")
Neutropenie und ihr Management bei Krebspatienten unter Chemotherapie49,90 €![Determining resectability in pancreatic tumors]( "Determining resectability in pancreatic tumors")
Determining resectability in pancreatic tumors26,99 €![Overview of Anemia and Thrombocytopenia in Cancer Patients]( "Overview of Anemia and Thrombocytopenia in Cancer Patients")
Overview of Anemia and Thrombocytopenia in Cancer Patients29,99 €![Natural product based promising apoptotic inducers]( "Natural product based promising apoptotic inducers")
Natural product based promising apoptotic inducers23,99 €![Introduction to Small and Non- Small Lung Cancer Patients]( "Introduction to Small and Non- Small Lung Cancer Patients")
Introduction to Small and Non- Small Lung Cancer Patients46,99 €![A Closer Look at Neutropenia in Solid and Hematological Cancers]( "A Closer Look at Neutropenia in Solid and Hematological Cancers")
A Closer Look at Neutropenia in Solid and Hematological Cancers19,99 €
This book provides guidance to oncologists responsible for reducing neutropenia and its management in cancer patients on chemotherapy. Evaluating results from the study and performing risk assessments associated with neutropenia, will be particularly useful to physicians to choose the right kind of treatment in reducing neutropenia. This study presents insights into future directions of oncology field into right kind of treatment in different modalities of cancer patients with solid tumors and lymphoma. Neutropenia is an important side effects and a major cause of morbidity and mortality in patients with cancer. The risk of infection is related to the intensity and duration of immunosuppressive chemotherapy. Various types of growth factors and cyto-protectant can be combined with the goal of increasing efficacy of chemo drugs and reducing different types of toxicities. In this text we have compared the efficacy of growth factor and cyto-protectant drug, randomly and cross over. This text can provide insight to the consultants to design that cyto-protectant drug administration followed by growth factors is beneficial treatment to reduce the complications of cancer chemotherapy